Linperlisib [1702816-75-8]
Referentie T6330-10mg
Formaat : 10mg
Merk : TargetMol
Linperlisib
(Synonyms: PI3Kδ-IN-2) Copy Product Info
Linperlisib (PI3Kδ-IN-2) is a potent and selective inhibitor of PI3Kδ
Cas No. 1702816-75-8
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.01%
Appearance:Solid
Color:White
COA HNMR LCMS
Product Introduction
Linperlisib AI Summary
Linperlisib inhibits SARS-CoV-2 3CL-Pro protease by 5.13% at a 20 µM concentration through a FRET response from a peptide substrate. Additionally, it exhibits antiviral activity against SARS-CoV-2 by inhibiting cytotoxicity in VERO-6 cells at a 10 µM concentration after 48 hours of viral exposure, although the assay results indicate an inhibition rate of -0.26%..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Linperlisib (PI3Kδ-IN-2) is a potent and selective inhibitor of PI3Kδ |
| Targets & IC50 | PI3Kδ:6.4 nM |
| Synonyms | PI3Kδ-IN-2 |
| Molecular Weight | 588.69 |
| Formula | C28H37FN6O5S |
| Cas No. | 1702816-75-8 |
| Smiles | COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1 |
| Relative Density. | 1.355 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 98 mg/mL (166.47 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 9.8 mg/mL (16.65 mM), Solution. 10% DMSO+90% Saline: < 9.8 mg/mL (16.65 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||